News

Reverdia starts its bio-succinic acid plant
Enlarge image

BusinessItalyNetherlandsFrance

Reverdia starts its bio-succinic acid plant

17.12.2012 - Reverdia has started industrial production of bio-succinic acid at a new production plant with an annual capacity of 10,000 metric tons.

The joint venture between Dutch DSM NV and French starch producer Roquette Frères has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium™ sustainable succinic acid. The company said the plant, which has a capacity of about 10,000 tonnes/yr, was unique in its kind, being the world’s first dedicated large-scale plant for the production of succinic acid from renewable resources. However, according to US-based BioAmber Inc, which fused BioAmber SAS and US company DNP Green Technology in 2010, it has been producing the chemical building block at 4,000 tonnes/yr since 2009.

Both producers rely on genetically engineered E.coli strains for producing the compound, that is being used to make bioplastics, chemical internmediates such as 1,4 butanediol, solvents, coatings, and phthalate-free plasticisers. As the market for bio-based succinic acid is expected to grow rapidly in the next few years, other joint-ventures such as Succinity or US-based Myriant Inc. are building production facilities. Reverdia will market its bio-succinium in collaboration with Helm.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-starts-its-bio-succinic-acid-plant.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTECH PHARMACON (N)16.80 NOK17.07%
  • ALMIRALL (E)17.26 EUR4.61%
  • EUROFINS SCIENTIFIC (F)301.96 EUR4.16%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • DBV TECHNOLOGIES (F)67.75 EUR-7.57%
  • CO.DON (D)2.50 EUR-7.41%

TOP

  • KARO BIO (S)39.30 SEK2371.7%
  • BIOTECH PHARMACON (N)16.80 NOK77.8%
  • TRANSGENE (F)4.92 EUR71.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.86 EUR-43.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-41.2%

TOP

  • KARO BIO (S)39.30 SEK4692.7%
  • ADOCIA (F)82.29 EUR384.9%
  • VERONA PHARMA (UK)5.00 GBP316.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • EVOCUTIS (UK)0.18 GBP-81.2%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-80.1%

No liability assumed, Date: 01.09.2015